A Case-Based Focus on Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Join the experts for a 70-minute interactive program featuring data review and case-based discussion on the application of current and emerging therapies for the treatment of neurofibromatosis type 1 and inoperable plexiform neurofibromas. Gain insights for your practice through clinical analysis of a variety of patient case scenarios.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Introduction
  • Disease Overview and Role of Targeted Treatment
  • Clinical Considerations and Management – Case Study Discussions
  • Remaining Questions and Future Directions – Open Discussion
  • Audience Question and Answer Session


Date / Time
Event Details


Miriam Bornhorst, MD

Clinical Director, Gilbert Neurofibromatosis Institute
Children’s National Hospital
Washington, DC

Carlos Romo, MD

Assistant Professor of Neurology, Oncology and Medicine Director of Clinical Research
The Neurofibromatosis Therapeutic Acceleration Program
Department of Neurology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Goal Statement
The goal of this activity is to improve the knowledge and competence of pediatric medical oncologists and other healthcare professionals who use novel targeted therapies in the treatment of pediatric patients with NF-1 plexiform neurofibromas.

Target Audience
This activity is intended for pediatric oncologists and other healthcare professionals who care for pediatric patients with neurofibromatosis type 1 who have inoperable plexiform neurofibromas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate the mechanisms of action of therapeutic approaches targeted to cell signaling pathways affected in NF-1
  • Describe to patients’ parents and caregivers the currently approved and emerging therapeutic strategies for the treatment of NF-1 and inoperable plexiform neurofibromas
  • Plan the use of novel targeted agents for patients with neurofibromatosis type 1 who have inoperable plexiform neurofibromas, taking into consideration available safety, efficacy, and quality of life data
  • Manage adverse events associated with approved targeted systemic treatments


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.